RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

aiming,

The problem isn't only whether the cellular problem will show up in the longer-term studies--and gfp is right when he says it probably will, given the dosages--but, rather, even if the longer-term studies are clean toxicology-wise (and even clean cellular-wise), COR has no explanation as to why the histopath abnormalities came up in the first place. Wth COR having to present this data to a new division in the FDA, if they want to proceed in ADHD, there is no guarantee that even "clean" findings will be enough to get the FDA to approve further, longer-term studies with CX717. I'd say CX717 is toast in ADHD. And, of course, that includes any hopes of partnering anytime soon.

We'll be lucky if we don't get more than a 50% haircut tomorrow, and that means the financing will have to be done at the $1.25/1.50 range. Not a pleasant thought.


This is really a disaster. And Stoll's downbeat assessment--what else could he say?--confirms that view. Even his rosy interpretation at the end cannot overcome seeing this for what it really is.


Bladerunner